My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
BARRANCO CASTANEDA, G; POSADA GALARZA, MER and OROPEZA CORNEJO, R. Management of the drug interaction between rivastigmine and tolterodine in one elderly patient with Parkinson and overactive bladder. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.4, pp.343-346. Epub May 25, 2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000400015.
The use of anticholinergic and cholinesterase inhibitors set is not recommended by drug laboratory producers, because the use of the drugs can affect the cognitive function of the patients, this is more common in the elderly and polymedicated population. For the pharmacist is a challenge to have control of the number of potential drug interactions that can express with the different drugs that the patient has in a prescription. We present a case of an expression of drug-drug interaction between anticholinergic (tolterodine) and direct cholinesterase inhibitor (rivastigmine) in a patient with Parkinson disease and overactive bladder, the outcome of this interaction is the decrease the effect of rivastigmine by inhibition of cholinergic receptors, keep the inhibition of release acetylcholine and remove the target of the enzyme that rivastigmine inhibit, the expression of the interaction in the patient is expressed in loss of concentration and memory, the management and report of this interaction is very important for the patient with control of the disease.
Keywords : Parkinson; tolterodine; rivastigmine; interaction; inhibition; anticholinergic.